openPR Logo
Press release

Shingles Vaccines Market Study Offering Deep Insight Related to Growth With Global Players GlaxoSmithKline (GSK), Zostavax

02-28-2019 12:54 PM CET | Health & Medicine

Press release from: Coherent Market Insights

Global Shingles Vaccine Market

Global Shingles Vaccine Market

The shingles vaccine market revenue is expected to grow at a robust rate over the forecast period. Shingles, also known as herpes zoster, is a viral infection that affects the cranial nerves that originate in the brain. It is caused by the varicella zoster virus, the same virus that also cases chicken pox. The virus can stay dormant for many years in the human body. Therefore, anyone who has had chicken pox in the past is at the risk of developing shingles. According to the Center for Disease Control and Prevention (CDC), there are an estimated one million cases of shingles reported every year in the U.S. Moreover, CDC states that around one in every three people in the U.S. will develop shingles in their lifetime. The risk of shingles increases with age, with most cases reported among people over 40 years old. This is mainly due to weakening of the immune system on account of increased stress and inadequate intake of essential nutrients to keep immunity strong.

For In depth Information Get Sample Copy of this Report @ https://bit.ly/2Nu4SMn

Symptoms include skin rashes, nerve pain, vision loss, chills, upset stomach, muscle weakness, skin infection, and scarring. Treatment for shingles includes antiviral medication—acyclovir, valacyclovir, and famciclovir. These medicines help shorten the length and alleviate the severity of the illness. Further, analgesics may help relieve the pain.

Shingles Vaccine Market Dynamics:

There is a safe and effective vaccines available for preventing shingles. The Zostavax vaccine licensed by Merck & Co., Inc. in 2006 is an effective vaccine against shingles. The vaccine is intended for use in population over 50 years of age. The trials of the Zostavax vaccine demonstrated that the vaccine was 64% effective in people aged 60 to 69 years. The effectiveness reduces with increasing age i.e. to 41% for the 70–79 age group, and 18% for those 80 years of age and older. The vaccine was launched in the India market in February 2016, at half the price of the U.S. market. Zostavax, among the only shingles vaccine in the market, recorded sales of US$ 749 million in 2015.

In October 2016, GlaxoSmithKline (GSK)—a global leader in vaccines market—filed for U.S. FDA approval for its shingles vaccine, Shingrix. Shingrix has demonstrated better outcomes than Zostavax in its clinical trials. The vaccine was 90% efficacious in people over 70 years of age. The overall effectiveness of the vaccine is found to be 97%. Its higher effectiveness even among elder group of people is projected to increase its adoption across the globe. The impressive trail results would put Shingrix in a strong competitive position in the global market, currently monopolized by Zostavax. The company is reported to have filed for regulatory approvals in the Europe and Canada markets in 2016, followed by Japan in 2017. It is estimated that the sales of Shingrix would reach US$ 1 billion by 2021.

Shingles vaccines market is witnessing rapid influx of newer and expensive products. The industry is consolidated in nature however, new entrants are expected to emerge in the near future.

Browse Complete Report For More Information @ https://bit.ly/2Nsl5lb

Shingles Vaccine Market Regional Analysis:

North America and Europe are expected to collectively account for a major share of the market between 2016 and 2024. North America market growth is primarily driven by rising demand in the U.S., while the market in Europe is expected to be driven by increased therapeutic demand from European Union.

Asia Pacific shingles vaccine market is expected to witness highest growth over the forecast period. There is a wide addressable market that needs to be capitalized upon in the region especially in China and India. Active marketing and differential pricing would help companies to strengthen their market presence in Asia Pacific.

Shingles Vaccine Market Opportunity:

Prevalence of shingles is increasing across the globe, fuelled mainly by increasing aging population. However, high cost of vaccines is limiting vaccination drive in emerging economies, characterized by inadequate insurance coverage. The major concern among healthcare experts is reduction in postherpetic neuralgia from the shingles vaccine. Zostavax has been successful to a certain extent in reducing postherpetic neuralgia due to the effect of the vaccine on reducing risk of developing herpes zoster. Better outcomes of Shingrix would be a boon for highly lucrative global shingles vaccines market.

Request For Customization of Research Report @ https://bit.ly/2U7ntjz

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at sales@coherentmarketinsights.com

https://www.coherentmarketinsights.com/phase-xs/

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Shingles Vaccines Market Study Offering Deep Insight Related to Growth With Global Players GlaxoSmithKline (GSK), Zostavax here

News-ID: 1623853 • Views: 335

More Releases from Coherent Market Insights

Oat Drink Market Is Set To Experience Revolutionary Growth By 2026 With Market P …
The report analysis the leading players of the Global Oat Drink Market by inspecting their market share, recent developments, new product launches, partnerships, mergers, or acquisitions, and their target markets. This report also includes an exhaustive analysis of their product profiles to explore the products and applications their operations are concentrated on in the global Oat Drink market. Additionally, the report gives two distinct market forecasts, one from the perspective
Bay Leaf Market Research Report 2026 Observational Studies with Key Vendors like …
The report analysis the leading players of the Global Bay Leaf Market by inspecting their market share, recent developments, new product launches, partnerships, mergers, or acquisitions, and their target markets. This report also includes an exhaustive analysis of their product profiles to explore the products and applications their operations are concentrated on in the global Bay Leaf market. Additionally, the report gives two distinct market forecasts, one from the perspective
Home Healthcare Software Future Growth with Top Players Agfa Healthcare, Mckesso …
Global “Home Healthcare Software Market” 2019 Research report provides information regarding market growth, cost structure, Keyplayers, revenue and forecast 2026. This report also includes the overall and comprehensive study of the Home Healthcare Software market with all its aspects influencing the growth of the market. This report is exhaustive quantitative analyses of the industry and provides data for making strategies to increase the market growth and effectiveness. Summary This report includes
Medical Cannabis Market Future Growth BOL Pharma, Tilray, Medreleaf, Aurora Cann …
Global “Medical Cannabis Market” 2019 Research report provides information regarding market growth, cost structure, Keyplayers, revenue and forecast 2026. This report also includes the overall and comprehensive study of the Medical Cannabis market with all its aspects influencing the growth of the market. This report is exhaustive quantitative analyses of the industry and provides data for making strategies to increase the market growth and effectiveness. Summary This report includes market status

All 5 Releases


More Releases for Shingles

Metal Roofing Highly Sought After Vis-à-vis Asphalt Shingles
There has been considerable growth in consumers’ interest in environmentally sustainable products. Metal roofs which usually contain 25% to 95% recycled content, and can be 100% recycled at the end of their life have been soaring in popularity. Few of the drivers in a building design’s success are lessening maintenance and operating costs while propelling energy efficiency. Given metal roofing positively influence building performance through providing durability, longevity and sustainability,
Shingles Vaccine Market Forecast by 2025: QY Research
In the recently published report, QY Research has provided a unique insight into the global Shingles Vaccine market for the forecasted period of 7-years (2018-2025). The report has covered the significant aspects that are contributing the growth of the global Shingles Vaccine market. The primary objective of this report is to highlight the various key market dynamics such as drivers, trends, and restraints that are impacting the global Shingles Vaccine
Herpes Zoster (Shingles) Market - Current Scenario and Forecast  2024
Herpes Zoster also known as zoster or shingles is a painful contagious viral disease which is characterized by blisters in limited area and painful skin rashes. These blisters full of liquid and pus appear on either side of the body or face, left or right in a single stripe. This disease is caused by varicella zoster virus which develops short lived or acute illness named as chickenpox that is usually
Herpes Zoster (Shingles) Market To Register Substantial Expansion By 2024
Herpes Zoster also known as zoster or shingles is a painful contagious viral disease which is characterized by blisters in limited area and painful skin rashes. These blisters full of liquid and pus appear on either side of the body or face, left or right in a single stripe. This disease is caused by varicella zoster virus which develops short lived or acute illness named as chickenpox that is usually
Shingles Vaccine Market
The shingles vaccine market revenue is expected to grow at a robust rate over the forecast period. Shingles, also known as herpes zoster, is a viral infection that affects the cranial nerves that originate in the brain. It is caused by the varicella zoster virus, the same virus that also cases chicken pox. The virus can stay dormant for many years in the human body. Therefore, anyone who has had
Herpes Zoster (Shingles) - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Herpes Zoster (Shingles) - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Herpes Zoster (Shingles) - Pipeline Review, H1 2017, provides an overview of the Herpes Zoster (Shingles) (Infectious Disease) pipeline landscape. Shingles (herpes zoster) is a painful, blistering skin rash. It is caused by the varicella-zoster